Pharmaceutical company Binnopharm Group estimates its business at more than ₽100 bln, the company's CEO Rustem Muratov told RBC Investments in an interview discussing a potential IPO. Binnopharm Group is interested in Chinese stock exchanges as an IPO platform, but in order to enter one of them it is necessary to first build a local business, which is what company is currently doing.